Arrowhead Pharmaceuticals, Inc.
ARWR
$17.67
$0.321.84%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -173.09M | -170.54M | -170.79M | -125.30M | -132.86M |
| Total Depreciation and Amortization | 5.24M | 5.03M | 4.78M | 4.53M | 4.26M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 29.02M | 20.34M | 25.95M | 25.03M | 21.63M |
| Change in Net Operating Assets | -7.44M | 7.95M | 24.64M | 3.37M | -10.87M |
| Cash from Operations | -146.27M | -137.22M | -115.42M | -92.38M | -117.84M |
| Capital Expenditure | -7.52M | -24.29M | -14.45M | -34.08M | -68.66M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 84.43M | -198.63M | 21.40M | -234.86M | 133.50M |
| Cash from Investing | 76.91M | -222.92M | 6.95M | -268.94M | 64.84M |
| Total Debt Issued | -- | 392.00M | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 634.00K | 223.00K | 387.00K | 430.78M | 267.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 20.00M | -3.13M | 50.00M | -- | -- |
| Cash from Financing | 20.63M | 389.09M | 50.39M | 430.78M | 267.00K |
| Foreign Exchange rate Adjustments | -68.00K | 4.34M | -223.00K | 26.00K | 58.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -48.80M | 33.29M | -58.31M | 69.49M | -52.68M |
